BPI-221351 / Betta Pharma - LARVOL DELTA

Discovery of BPI-221351, a potent, selective, orally available, and brain penetrating dual inhibitor of mutant IDH1/2 (AACR 2023) - "In addition, BPI-221351 possesses excellent blood-brain-barrier penetration with a higher drug concentration in the brain than that in plasma. In conclusion, BPI-221351 exhibits strong activity towards both IDH1 and IDH2 mutants in vitro and in vivo with favorable pharmacological properties, presenting a new therapeutic opportunity for treating glioma and other relevant cancers."

Acute Myelogenous Leukemia • Brain Cancer • CNS Tumor • Glioma • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • IDH1 • IDH2